Shire PLC (NASDAQ:SHPG) posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.64 by $0.17, MarketWatch Earnings reports. The firm had revenue of $3.70 billion during the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.17 EPS. Shire PLC updated its FY17 guidance to $14.80-15.20 EPS.
Shares of Shire PLC (SHPG) opened at $140.36 on Monday. The company has a market capitalization of $42,151.51, a PE ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire PLC has a 12 month low of $137.80 and a 12 month high of $192.15.
SHPG has been the subject of a number of research reports. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Barclays PLC lowered Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI assumed coverage on Shire PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price on the stock. Royal Bank Of Canada reaffirmed a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price objective on Shire PLC and gave the stock a “hold” rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $211.00.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/13/shire-plc-shpg-issues-quarterly-earnings-results-beats-estimates-by-0-17-eps.html.
Large investors have recently made changes to their positions in the business. Seizert Capital Partners LLC increased its stake in Shire PLC by 13.3% during the third quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after acquiring an additional 1,267 shares during the last quarter. Fisher Asset Management LLC increased its stake in Shire PLC by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after acquiring an additional 1,619 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in Shire PLC by 63.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after acquiring an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC increased its stake in Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 23 shares during the last quarter. Finally, Oak Ridge Investments LLC increased its stake in Shire PLC by 3.2% during the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock worth $13,389,000 after acquiring an additional 2,528 shares during the last quarter. Institutional investors own 19.24% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.